What is Advanced Medical Solutions Group EV-to-FCF?
Advanced Medical Solutions GroupCHIX:AMSL +14.17%93 EV-to-FCF is 33.51 as of Jun. 26, 2026, which is 3% above its 10-year median of 32.52. GuruFocus rates CHIX:AMSL with a GF Score™ of 93/100 and a GF Value™ of £3.71 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 61.52% on this metric.
The historical rank and industry rank for Advanced Medical Solutions Group's EV-to-FCF or its related term are showing as below:
CHIX:AMSl'
s EV-to-FCF Range Over the Past 10 Years
Min: 18.72 Med: 32.52 Max: 202.27
Current: 29.33
During the past 13 years, the highest EV-to-FCF of Advanced Medical Solutions Group was 202.27. The lowest was 18.72. And the median was 32.52.
CHIX:AMSl's EV-to-FCF is ranked worse than 61.52% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 22.82
vs CHIX:AMSl: 29.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advanced Medical Solutions Group (CHIX:AMSl) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advanced Medical Solutions Group's PE Ratio (TTM) for today is calculated as:
Advanced Medical Solutions Group's share price for today is £2.78.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.045.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Advanced Medical Solutions Group EV-to-FCF Related Terms
Advanced Medical Solutions Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMSL vs ISRG, BDX, MDLN: EV-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's EV-to-FCF falls into.
Advanced Medical Solutions Group's current Enterprise Value is £669.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Advanced Medical Solutions Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £20.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a EV-to-FCF of 33.51 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Advanced Medical Solutions Group and its competitors. This is near median its historical median of 32.52. Over the past decade, Advanced Medical Solutions Group's EV-to-FCF has ranged from 18.72 to 202.27. According to the industry distribution chart, Advanced Medical Solutions Group ranks #259 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 61.5%.
Is Advanced Medical Solutions Group's EV-to-FCF too high?
Advanced Medical Solutions Group's current EV-to-FCF of 33.51 is near median its 10-year median of 32.52. Over the past 10 years, this metric has ranged from a low of 18.72 to a high of 202.27. The Medical Devices & Instruments industry median EV-to-FCF is 22.82. Advanced Medical Solutions Group's value of 33.51 is 46.8% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #259 out of 421 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #259 out of 421 companies for EV-to-FCF. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median EV-to-FCF is 22.82. Advanced Medical Solutions Group's value of 33.51 is 46.8% above this benchmark. Historically, Advanced Medical Solutions Group's own EV-to-FCF has ranged from 18.72 to 202.27 over the past decade. While the company's 10-year median is 32.52 vs. the industry median of 22.82, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.82, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current EV-to-FCF of 33.51 is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current EV-to-FCF is 33.51, which is near median its own 10-year median of 32.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.71, compared to a current price of £2.78 — trading 25.1% below its estimated fair value. The current EV-to-FCF is 33.51, which is near median its 10-year median of 32.52 and 46.8% above the Medical Devices & Instruments industry median of 22.82. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current EV-to-FCF is 33.51 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.78 is trading 25.1% below its estimated GF Value™ of £3.71.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
EV-to-FCF: 33.51 (near median its 10-year median of 32.52)
GF Value™: £3.71 vs. price of £2.78 (25.1% below fair value)
Industry Position: 46.8% above the Medical Devices & Instruments median (#259 of 421)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score
Get the complete analysis for CHIX:AMSL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
